| 查看: 506 | 回复: 4 | ||
| 【奖励】 本帖被评价3次，作者bio-polymer增加金币 2 个 | ||
| 当前主题已经存档。 | ||
[资源]
Nature Reviews: Drug Discovery - July 2008 - Vol 7 No 7
|
||
|
Volume 7, No 7 July 2008 Featured Article Purinergic signalling and disorders of the central nervous system Geoffrey Burnstock News and Analysis ASCO presentations highlight value of cancer biomarkers | PDF (717 KB) p547 | doi:10.1038/nrd2633 News Feature Nurturing European collaboration | PDF (445 KB) p548 | doi:10.1038/nrd2634 News in Brief DPP4 inhibitors prominent at ADA meeting | Biomarkers get transatlantic approval | First miRNA clinical trial | GSK announces restructuring | Recent acquisitions expand pipelines and diagnostics | Sentinel initiative outlined | PDF (759 KB) p550 | doi:10.1038/nrd2635 Patent watch Supreme Court decides on patent exhaustion | More good news for Lipitor patent | P2X and P2X puringeric receptors | PDF (357 KB) p552 | doi:10.1038/nrd2632 An Audience With Ted Kaptchuk | PDF (144 KB) p554 | doi:10.1038/nrd2629 From the analyst's couch Novel agents in cystic fibrosis | PDF (265 KB) p555 | doi:10.1038/nrd2603 Fresh from the Pipeline Dabigatran etexilate | PDF (253 KB) p557 | doi:10.1038/nrd2622 Top of page Research Highlights Eye diseases: Convenient leakage reduction | PDF (163 KB) p559 | doi:10.1038/nrd2630 Metabolic disease: Blocking brain enzyme curbs appetite | PDF (265 KB) p560 | doi:10.1038/nrd2621 Vaccines: Mast cells key to new vaccine adjuvants | PDF (191 KB) p560 | doi:10.1038/nrd2628 Monoclonal antibodies: Expanding the mAb pool | PDF (175 KB) p561 | doi:10.1038/nrd2625 In brief Obesity | Viral infection | Anticancer drugs | Virtual screening | PDF (152 KB) p562 | doi:10.1038/nrd2626 Leukaemia: Targeting silent cells | PDF (410 KB) p562 | doi:10.1038/nrd2627 Perspectives Outlook What drives success for specialty pharmaceuticals? Mark Gudiksen, Edd Fleming, Laura Furstenthal & Philip Ma p563 | doi:10.1038/nrd2594 Specialty pharmaceuticals — drugs prescribed primarily by specialists rather than primary-care physicians — have become an increasingly important part of the global pharmaceutical landscape. Ma and colleagues analyse the key factors influencing the commercial success and failure for specialty pharmaceuticals. Opinion Creating and evaluating genetic tests predictive of drug response Scott T. Weiss, Howard L. McLeod, David A. Flockhart, M. Eileen Dolan, Neal L. Benowitz, Julie A. Johnson, Mark J. Ratain & Kathleen M. Giacomini p568 | doi:10.1038/nrd2520 Recent advances in genomic knowledge and associated technologies should help accelerate the development of genetic tests that can predict drug response and toxicity; however several challenges remain. Here, Weiss and colleagues discuss the factors that affect the development, performance and uptake of pharmacogenetic tests. Reviews Purinergic signalling and disorders of the central nervous system Geoffrey Burnstock p575 | doi:10.1038/nrd2605 There is increasing interest in the role of purinergic signalling in CNS disorders, but few modulators have reached the clinic. Here, Burnstock provides an overview of the role of purinergic signalling in specific disorders, including brain trauma, ischaemia, neurodegenerative, neuroinflammatory and neuropsychiatric diseases, and highlights specific purinergic receptor subtypes that represent promising therapeutic targets. Molecular imaging in drug development Jürgen K. Willmann, Nicholas van Bruggen, Ludger M. Dinkelborg & Sanjiv S. Gambhir p591 | doi:10.1038/nrd2290 Molecular imaging, which can allow the non-invasive monitoring of biological processes in living subjects, has the potential to enhance understanding of disease and drug activity in both preclinical and clinical drug studies, aiding effective translational research. Gambhir and colleagues review the applications of molecular imaging in drug development, and discuss challenges that need to be addressed to optimize its utility. The exploration of macrocycles for drug discovery — an underexploited structural class Edward M. Driggers, Stephen P. Hale, Jinbo Lee & Nicholas K. Terrett p608 | doi:10.1038/nrd2590 Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents. Despite this, macrocyclic compounds remain under-explored. Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocyles in drug discovery. Careers and Recruitment Laboratory automation p625 | doi:10.1038/nrd2624 http://ifile.it/8jt3mxr/nr-dd708.rar |
回复此楼» 猜你喜欢
关于filecode，很负责任的告诉大家
已经有7人回复
-
【2027博士申请】纳米药物递送方向
已经有5人回复
-
关于豆爷回答的JTJC与%2F数量
已经有7人回复
-
2026国自然放榜时间
已经有3人回复
-
国基金的申报应该改成非等额制，评价高的钱多评价低的钱少，但是增加资助率
已经有7人回复
-
好奇怪的filecode
已经有4人回复
-
售SCI文章，我:8O5.5.1.O.54,科目齐全,可+急
已经有4人回复
-
售SCI一区T0P文章，我:8.O.55.1.O54,科目全,可伽急
已经有4人回复
-
售SCI文章，我:8O.5.5.1O.54,科目全,可十急
已经有4人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.54,科目齐全,可+急
已经有5人回复
，谢谢楼主 3楼2008-10-04 22:00:52
简单回复
2008-09-30 23:15
回复
20